Asker’s $888.1 million IPO on the Nasdaq Stockholm is the largest healthcare IPO of the year so far, according to the DNB and Back Bay report. That could bode well for commercial-stage Caris.

As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical ...

U.S. stock futures are edging lower as investors digest President Donald Trump's comments on Iran, while shares of Accenture ...

Explore Passage Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PASG.

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on June 24, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

A high-level overview of Passage Bio, Inc. (PASG) stock. View ... IPO Update: Passage Bio Finalizes $126 Million IPO Plan ... Is Passage Bio, Inc. listed on the NASDAQ or NYSE?

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Data from Renaissance Capital shows that year-to-date, 100 IPOs have been filed—an increase of 19% from last year—and that 81 have priced, an increase of 40%.

MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction ...

TELA Bio, Inc., a medical technology company specializing in soft-tissue reconstruction solutions, has announced the appointment of Jeffrey Blizard as President, effective immediately. Blizard ...

Exchange operator Nasdaq is holding active talks with companies considering stock market debuts, CEO Adena Friedman said on Thursday, underscoring the U.S. economy's resilience despite tariff ...